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Executive Summary 
 
Transdermal drug delivery systems are involved in the continuous administration of drug 
molecules from the surface of the skin into the circulatory system.  Such systems have proved 
advantageous for delivery of certain drugs, such as scopolamine, nicotine, nitroglycerine, and 
estradiol. Compared with oral administration, transdermal drug delivery offers better uniformity 
of drug concentrations in plasma throughout their duration of use.  Scopolamine is the active 
ingredient in motion sickness medication that targets the nerve fibers in the inner ear.  The 
scopolamine patch is effective for about three days, longer than if administered orally which is 
effective for only several hours.  One of the main restraints of this transdermal system is its 
absorption through the skin, especially through the stratum corneum, its outermost part.  This 
study examines the rate of diffusion of transdermal scopolamine across the skin and into the 
systemic circulation. Our objective is to optimize the drug delivery by way of a scopolamine 
patch by minimizing absorption rates, while maintaining its advantage of a long-term effect.  A 
comparative study of the effects in the presence of penetration enhancers were undertaken to 
show how steady state is approached at different rates.  The model we used does offer certain 
limitations, as diffusivity values specific to human skin and scopolamine are not readily 
available. 
 
 
Introduction and Design Objectives 
 
Motion sickness is a common ailment that many individuals experience in the form of sea 
sickness, car sickness, or air sickness.  Motion sickness occurs when the body is subjected to 
accelerations of movement in different directions.  This movement causes the balance center of 
the inner ear to send conflicting information to the brain that differ from any visual cues that 
indicate an apparent stillness.  Despite these prevention methods, medication specifically 
designed to control such a condition is the most effective.  Even with prescriptions and over the 
counter oral medications to prevent or limit symptoms, drugs effective until one hour after they 
are administered.  This is best for individuals who are aware of their tendency to experience 
motion sickness while on a plane, ship, or car.  Oral medication is most effective for short trips 
or when symptoms occur intermittently. Alternatively, for those interested in a long-term effect 
(i.e. 3 days), the transdermal drug delivery method is most effective.  
 
The commercially available scopolamine patch is Transderm-Scop.  It is to be placed on the skin 
behind the ear approximately four hours before the effects will be needed. The Transderm-Scop 
is programmed to deliver in-vivo approximately 1.0 mg of scopolamine over three days. As with 
other transdermal drug systems, scopolamine delivery is hindered by skin permeability, including the stratum corneum, which is perhaps the major physical barrier.  Once diffusion 
through the stratum corneum is achieved, the molecules diffuse through the dermis, are absorbed 
into capillary beds, and then circulate to the targeted area.   
 
Our objective is to model the absorption of scopolamine through the skin to reach systemic 
circulation.  Fick’s law of diffusion is implemented to model the delivery of the drug across a 
membrane, in this case the skin.  The different regions of diffusion that we take into account are 
the epidermis and the dermis. The epidermis is the outermost layer of the skin where hair 
projects out from the pores of the skin. This layer consists of free sensitive nerve endings as well. 
Next, the dermis layer consists of sweat glands and sebaceous glands as well as collagen fibers. 
 
The first model used was an axi-symmetric model of epidermis and dermis with zero flux at the 
side boundaries, as shown in the figure below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Dimensions of Human Skin Model 
 
In addition, we will also model the diffusion in the presence of “penetration enhancers” such as 
nonanoic acid and oleic acid, and compare how much the rate of penetration is increased.  Once 
applied, a patch alone should take four hours to achieve its desired effect.  We expect this initial 
time of action to decrease when accompanied with a penetration enhancer. 
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For our solution, we calculated our first diffusivity value from permeability constant, partition 
coefficient, and rat skin values from a study by Calpena, A.C. et. al. (See appendix for actual 
values and calculations) 
 
After running the program with these values and the appropriate boundary and initial conditions, 
our solution showed that steady state was reached at around 40hours, as can be observed in the 
figure below. Node 212 is shown in Fig B1 and B2 in Appx B. The contour plots at steady state 
are shown in Fig B5 and B6. 
 
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
Fig 2. History Plot of Original Model at Node 212 (reaches steady state at 40hrs) 
 
 
 
However, in a study of scopolamine absorption in humans by Muir, C. and Metcalf, R., steady 
state was reached after 8 hours of application of the patch.  Based on these findings, we decided 
to use the software to determine (by iteration) the diffusivity value that would lead to such steady 
state.  The following plot was obtained to confirm that steady state was achieved after roughly 
eight hours. The contour plots are shown in Fig B3 and B4. 
 
 
 
     
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. History Plot of Model at Node 212 with Diffusivity Values Found by Iteration  
(reaches steady state at 8hrs) 
 
 
Compared to our first set of values, the values obtained from the program are off by a magnitude 
of 10.  This may be explained by the errors that may result from obtaining values based on rat 
skin properties, which will undoubtedly be different from human skin.  Skin from the dorsal side 
of rats might be substantially different from the skin in the post-auricular area of humans.   
Likewise, the experimental results obtained from the rat study involved the use of Franz 
diffusion cells, which may also have an effect on the permeability rate constants that were 
determined (and that we used to calculate diffusivity). 
 
It was thought to be realistic to add an extra skin entity to find out how much of the chemical 
would diffuse outwards, therefore transforming from a 1D to a 2D problem. The diffusivity 
values used for this case were the ones that gave us 8hrs to steady state. We ran the program 
again to show a more accurate model that allows diffusion to take place outwards (horizontally) 
along the side boundaries (see below).  We were interested in seeing how the species 
concentration at different times and regions varies with this new model, as well as how it affects 
the time to get to reach steady state. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6. Model of Human Skin with Extra Skin Entity Included 
 
 
Our solution shows that there is indeed some outwards diffusion, as the following contour plot 
shows. As we can see in the figure below, our outer boundaries are far enough such that the 
species concentration side edges are zero.  (Note that the set of diffusivity values we used in this 
analysis is the one that gives steady state concentration in the skin after 8hrs in our original mesh 
without the skin extensions). The mesh is shown in Fig B7 and B8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7. Contour Plot of Human Skin with Extra Skin Entity Included 
Patch (same size as previously) 
Extra Skin Entity  
The following graph is the history plot of species concentration at node 250, which is right at the 
interface between the epidermis and dermis. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8. History Plot at Node 250 (Human Skin with Extra Skin Entity Included) 
 
 
 
Mesh Convergence Investigation 
 
In order to see whether our mesh definition is appropriate (i.e. we have achieved mesh 
convergence), making a finer mesh (i.e. incorporating more elements) should not change the 
solution. The conventional approach is to create a similar model with the same geometry with 
increased elements, and strive to find a mesh definition that strikes a balance between 
computation time and quality of solution. However, since our mesh seems to converge already, 
we decided to create another mesh with much fewer elements to contrast this mesh, as the one 
below. The overall mesh is shown in Fig B10. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. Unrefined Mesh (zoomed in at Node 4)  
 
Our results indicate that our initial, finer mesh displays similar results (i.e. steady state after 8 
hours) but also takes care of the irregular jump at the beginning of the process, that is shown in 
the following figure using the mesh with fewer elements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. History Plot of Unrefined Mesh at Node 4 
 
 Sensitivity Analysis 1 – Removal of Patch after 30hrs (with extra skin entity) 
 
In addition, we wanted to model how long it takes for the drug to diffuse through the skin once 
the patch is removed (with extra entity still in place).  In other words, we were interested in the 
diffusion profile once the constant flux of 5.56 x 10
-3 mg/cm
2/hr on the top surface is removed.  
We wanted to know how long it takes for the drug to diffuse out of the skin, and thus, how long 
after the patch is removed will the drug be circulating in the system.  For this purpose, we 
decided to have a constant flux for 30 hrs, after which the patch would be removed and the flux 
would then be = 0 mg/cm
2.  Our results showed that once the patch is removed after hour 30, it 
takes about 15 hours for the drug to diffuse out of the region, as is revealed in the following plot. 
Node 437 is shown in Fig 9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9. History Plot at Node 437 (Human Skin with Extra Skin Entity Included, but with patch 
removed after 30hrs) 
 
 
 
 
 
 
 
 
 
 Sensitivity Analysis 2 – Temperature Enhancement and Penetration 
Enhancers 
 
We also measured sensitivity to diffusivity based on changes in temperature and chemical 
enhancers. It is found that heat raises diffusion rates, increasing flux to as much as twice its 
original value. This happens due to increased body fluid circulation, blood vessel wall 
permeability and drug solubility etc. The results we obtained with a diffusivity value of twice the 
original value are represented in the following figure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. History Plot at Node 212 (with Temperature Enhancement) 
 
The plot indicates that a twofold increase in diffusivity achieves steady state after approximately 
six hours. 
 
 
In addition, we tested the effect of two chemical penetration enhancers.  An article by 
Kanikkannan indicates that the chemical nonanoic acid has an enhancement factor of 
approximately 3.83.  Based on this data, we ran our program with the original diffusivity 
increased by the above factor to obtain the following results: 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 11. History Plot at Node 212 (with nonanoic acid) 
 
The plot indicates that steady state is reached three hours after the patch is applied. 
 
Similarly, the Kanikkannan study that oleic acid has an enhancement factor of 5.35.  Based on 
this data, the following results were obtained: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12. History Plot at Node 212 (with oleic acid) Discussion and Conclusions 
 
The results we obtained correspond to what we expected.  Because the patch is designed to have 
a controlled release rate and to provide relief for up to three days, we were aware that steady 
state would be reached after a certain time in order to sustain the provision of scopolamine to the 
systemic circulation at a controlled rate.   
 
Likewise, we were also able to model how long it takes for the drug to diffuse out of the skin 
once the patch is removed.  This can be useful since some users may present side effects or skin 
irritation to prolonged use of the patch and it may be useful to know how long the drug is in the 
skin (or in the systemic circulation) once the flux is cut off.  Also, for those users who are 
interested in using the patch for less than its full capacity (three days), it is practical to know how 
much longer the effects of the patch would last once it is removed, to determine when they 
should remove it.  Furthermore, manufacturers can use this data to produce patches with different 
capacities that suit varying needs. 
 
Finally, we were able to study how the patch can be improved by increasing temperatures or 
incorporating chemical enhancers, which all achieve a steady state process at shorter times.  With 
these variations, the user may not need to wait four hours before achieving the desired effects of 
the drug (as the current scopolamine patch requires).  However, from these studies, we are 
unable to determine exactly how much shorter this time would be since we did not model the 
process once the drug reaches systemic circulation. 
 
In general, FIDAP served as a useful tool to study transdermal delivery systems by providing 
with the possibility of changing the model (i.e. changing parameters) and observing the 
appropriate results.  For instance, we were able to see how increasing the diffusivities affect the 
process quantitatively.  Nevertheless, the use of FIDAP presupposes the availability of empirical 
data, in this case diffusivity values and skin properties.  This was a challenge for our analysis 
since we were unable to find any previous study that had diffusivity values specific for 
scopolamine in post-auricular skin.  For this reason, we had to use data on rat studies, which 
undoubtedly introduces errors.  Likewise, the use of our program to determine diffusivity values 
assumes that our model is right.  However, given that we are lumping the multiple skin variations 
and properties into just two regions (epidermis and dermis) we are bound to have an 
oversimplified model.  Hence, this leads to less accurate diffusivity values.  Appendix A 
 
Geometry  
 
The geometry of the epidermis is based on the average thickness of the epidermis and the dermis 
layers in the post-auricular region, where the patch is normally applied. The cross sectional area 
of the patch is typically 2.5cm
2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig A1. Original Model with Extra Skin Entity 
 
The mesh we created has an extension that expands radially by 4.45 mm (equivalent to 50% of 
the patch radius).  It looks as follows: 
 
 
                     ‘EPIDERMIS ADD’                     ‘DERMIS ADD’: flux = 0   
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              Flux = 0 at ‘MIDDLE’  (axis-symmetric) 
 
Fig A2. Axisymmetrical Model of Human Skin with Extra Skin Entity 
 
There is a constant flux of 5.56 x 10
-3mg/cm
2/hr at ‘TOP SURFACE’, where the patch is located.  
 
 
 
Patch Governing Equation 
 
 
 
 
 
 
where CD = concentration of the drug; u = velocity due to convective flux;  t = time; x = distance 
from top; DD  = diffusivity constant of scopolamine; and r  = generation/metabolism of 
scopolamine in dermis.  In this model, we are dealing with a solid (i.e. no fluid flow), therefore 
the velocity term is eliminated.  Likewise, there is no storage/metabolism of scopolamine in the 
skin, and therefore, the reaction term is also zero. 
 
Boundary Conditions 
 
The scopolamine patch is programmed to deliver in-vivo approximately 1.0 mg of scopolamine 
at an approximately constant rate to the systemic circulation over 3 days.  Thus, the controlled 
release rate is of 0.0139mg/hr. With a patch area of 2.5cm
2, a constant flux of 5.56 x 10
-3 
mg/hr/cm
2 is achieved at the top boundary (x=0), where the patch is located. For the bottom 
boundary beneath the dermis, it is assumed that the rate of blood flow transports the scopolamine 
fast enough such that concentration is zero (there is no building up of scopolamine at the bottom 
boundary). 
 
Thus, the boundary conditions are: 
 
•  -D(dC/dx) = 5.56 x 10
-3 mg/hr/cm
2 at ‘TOP SURFACE’ 
•  C = 0 at ‘BOTTOM’ and ‘BOTTOM ADD’ 
•  -D(dC/dx) = 0 mg/hr/cm
2  at ‘MIDDLE’, ‘TOP ADD’,  
                                  ‘EPIDERMIS ADD’, and ‘DERMIS ADD’ 
 
Initial Conditions 
 
•  C = 0 at t = 0 for all x.  
 
 
Input parameters 
 
 
Post auricular skin properties 
 
 
Epidermis thickness  0.1 mm  (Lee, Y. and K. Hwang, 2002) 
Dermis thickness  0.5 mm  (Lee, Y. and K. Hwang, 2002) 
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A) From formula 
 
From the study of transdermal absorption of scopolamine in rats by Calpena, A.C. et. al, we took 
values of permeability rate constant obtained experimentally for scopolamine, the partition 
coefficient in octanol-water for scopolamine, and the average rat epidermis thickness to calculate 
the diffusivity of scopolamine based on the following relationship  Kp = D* po/w / d , where Kp is 
the permeability rate constant, D is the diffusivity, po/w is the partition coefficient, and d is the rat 
epidermis thickness 
 
 
Diffusivity in epidermis  (from 
formula)  5.23 x 10
-6 cm
2/hr  (Calpena, A.C. et. al, 1993) 
Diffusivity in dermis 
(assuming 400 times 
diffusivity in epidermis)  0.002 cm
2/hr  (Dalby, R., 2001) 
 
B) From FIDAP 
 
In a study of scopolamine absorption in humans by Muir, C. and Metcalf, R., steady state was 
reached after 8 hours of application of the patch.  Based on these findings, we decided to use the 
software to determine the diffusivity value that would lead to such steady state.  
 
Diffusivity in epidermis  (from 
FIDAP)  2.0 x 10
-4 cm
2/hr  (Muir, C. and R. Metcalf, 1983) 
Diffusivity in dermis 
(assuming 400 times 
diffusivity in epidermis)  0.008 cm
2/hr  (Dalby, R., 2001) 
 
C) Enhanced diffusivities using qualitative data 
Based on qualitative data obtained in various sources, we enhanced the diffusivity by factors of 2 
(diffusivity enhanced by increase in temperature); 5.35 (diffusivity increased with oleic acid as 
chemical enhancer); and 3.83 (diffusivity increased with nonanoic acid as chemical enhancer). 
 
 
 
 Diffusivity with increased 
temperatures in epidermis  1.046 x 10
-5 cm
2/hr (Hull,  W.,  2002) 
Diffusivity with chemical 
enhancer oleic acid in 
epidermis         (enhancement 
factor of 5.35)  2.789 x 10
-5 cm
2/hr  (Kanikkannan, N, 2000 ) 
Diffusivity with chemical 
enhancer nonanoic acid in 
epidermis          
(enhancement factor of 3.83)  2.003 x 10
-5 cm
2/hr (Kanikkannan,  N,  2000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIDAP input parameters 
 
SIMULATION 
 
PROBLEM command:   
 
PROB (AXI-, INCO, TRAN, LAMI, LINE, NEWT, NOMO, ISOT, FIXE, NOST, NORE, SING, 
SPEC = 1.0) 
 
The design of our problem was modeled as axisymmetric in geometry.  Substances used for the 
model are all incompressible and Newtonian.  The problem analysis was performed in transient 
and not in steady state while any fluid flows were assumed to be laminar.  Convection was not 
considered in this problem, therefore resulting in a problem design without momentum analysis.  
The problem was isothermal due to assumed fixed temperatures, therefore excluding the energy 
equation.  The design was also modeled with fixed surfaces with no structural solver and no 
remeshing required.  The problem was assumed to be a single phase design.  Finally, only one 
species, scopolamine, was considered in this problem. 
 
EXECUTION and SOLUTION command: 
 
  EXEC (NEWJ) 
   SOLU (S.S. = 10, ACCF = 0.000000000000E+00) 
 
The newjob parameter in the execution command informs the program that this is a new 
problem.  The Solution command input parameters tell FIDAP to use successive substitutions to 
solve for each time step with a maximum number of iterations set at 10 for each step.  The 
acceleration of the solver is set at zero.   
 
TIMEINTEGRATION command: 
 
TIME (BACK, NSTE = 1000, TSTA = 0.000000000000E+00, TEND = 100.0, DT = 
0.100000000000E-05, VARI = 0.100000000000E-03, NOFI = 5, INCMAX = 2.0) 
             
The number of steps is set at 1000 while the starting and ending times of problem are set at 0 and 
100, respectively.   
 
ENTITY 
 
ENTI (NAME = "Epidermis", SOLI, SPEC = 1.0, MDIF = "scopoepidermis") 
ENTI (NAME = "Dermis", SOLI, SPEC = 1.0, MDIF = "scopodermis") 
ENTI (NAME = "Top Surface", PLOT) 
ENTI (NAME = "Bottom Surface", PLOT) 
ENTI (NAME = "Middle-Epidermis", PLOT) 
ENTI (NAME = "Middle-Dermis", PLOT) 
ENTI (NAME = "End-Epidermis", PLOT) 
ENTI (NAME = "End-Dermis", PLOT) 
 
 This step specifies each of the separate entities created for analysis of the problem.  In this case, 
we have 8 total entities including the epidermal and dermal layers of the skin, which are whole 
solid entities into which diffusion of the species, scopolamine, diffuses.  Additionally, the top 
and bottom surfaces of the skin, the middle axis of symmetry for the epidermis and dermis and 
the outer boundary of the epidermis and dermis regions are also specified as the boundaries of 
the model.         
 
PROPERTIES 
 
DIFFUSIVITY command: 
 
DIFF (SET = "scopoepidermis", CONS = 0.200000000000E-04) 
DIFF (SET = "scopodermis", CONS = 0.800000000000E-02) 
 
This command allows us to set the diffusivity property of scopolamine through the epidermal 
and dermal layers to constant numerical values. 
 
BOUNDARY CONDITIONS 
 
BCFLUX command: 
 
BCFL (SPEC = 1.0, ENTI = "Top Surface", CONS = 0.556000000000E-02) 
 
The set boundary condition for the top surface of the model was set to a constant 5.56E-3 
mg/hr/cm2 flux of scopolamine.  
 
BCNODE command: 
  
BCNO (SPEC = 1.0, ENTI = "Bottom Surface", ZERO) 
 
The boundary condition for the bottom surface of the element was fixed at a constant zero 
scopolamine value to insure no flux.   
 
INITIAL CONDITIONS 
 
ICNODE command: 
 
ICNO (SPEC = 1.0, ZERO, ALL) 
 
 The initial condition for the model was specified as a constant zero concentration of 
scopolamine in all of the entities.     
 
 
 
 
 
 
 Appendix B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig B1: Original Mesh of Human Skin (Epidermis and Dermis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig B2: Zoomed in Mesh showing Node 212 (Epidermis and Dermis)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B3. Contour plot at 8 hours for scopolamine diffusivity values of 0.2e-4 mg/cm
2/hr 
through the epidermis and 8e-3 mg/cm
2/hr through the dermis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B4. Contour plot at 8 hours (with scaling for dermis values) for scopolamine diffusivity 
values of 0.2e-4 mg/cm
2/hr through the epidermis and 8e-3 mg/cm
2/hr through the dermis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B5. Contour plot at 40 hours for scopolamine diffusivity values of 5.23e-6 mg/cm
2/hr 
through the epidermis and 2.0e-3 mg/cm
2/hr through the dermis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B6. Contour plot at 40 hours (with scaling for dermis values) for scopolamine diffusivity 
values of 5.23e-6 mg/cm
2/hr through the epidermis and 2.0e-3 mg/cm
2/hr through the dermis. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B7: New mesh with extra skin modeled. Node 250 is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Contour Plot at 8 hours 
 
 
 
 
 
 
Figure B8: New mesh with extra skin modeled. 
No Patch
Patch 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B9: Location of Node 437 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B10: Unrefined Mesh References 
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